PHARMACOECONOMIC EVALUATION OF MEROPENEM VERSUS IMIPENEM/CILASTATIN IN HOSPITAL AND VENTILATOR-ACQUIRED PNEUMONIA (HAP/VAP), ALEXANDRIA, EGYPT, 2017

Author(s)

Abdel-Aty ME1, Mohamed Ef2, Abdelmoneim SA3, Momtaz IM3, Ahmed Hassan Ef3
1University of Alexandria, Faculty of Pharmacy, Ministry of Health and Population, Mansoura, Egypt, 2University of Alexandria,Faculty of Pharmacy & Ministry of Health and Population, Alexandria, Egypt, 3University of Alexandria, Faculty of Pharmacy, Ministry of Health and Population, Alexandria, Egypt

Presentation Documents

OBJECTIVES: To evaluate the cost-effectiveness and cost-benefit of imipenem/cilastatin(2g daily) vs. meropenem(3g daily) in the management of Hospital and Ventilator Acquired Pneumonia (HAP/VAP) in hospitals of Alexandria, Egypt,2016-2017.

METHODS: The study was retrospective pharmacoeconomic evaluation

Conference/Value in Health Info

2018-05, ISPOR 2018, Baltimore, MD, USA

Value in Health, Vol. 21, S1 (May 2018)

Code

PRS26

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Respiratory-Related Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×